טוען...
MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity
Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by initial chemosensitivity followed by emergence of chemoresistant disease. To study roles for MYCN amplification in SCLC progression and chemoresistance, we developed a genetically engineered mouse model of MYCN-ove...
שמור ב:
| הוצא לאור ב: | Genes Dev |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Cold Spring Harbor Laboratory Press
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7462062/ https://ncbi.nlm.nih.gov/pubmed/32820040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.340133.120 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|